Navigation Links
Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
Date:5/15/2008

levels. For those patients with BMI greater than or equal to 30 kg/m(2), AZOR 10/40 mg demonstrated mean reductions of 30/18 mm Hg from an average baseline BP of 163/102 in the total cohort. Patients with BMI of less than 30 kg/m(2) saw BP reductions of 31/21 mm Hg when treated with AZOR 10/40 mg from an average baseline BP of 165/101 in total cohort.

DIABETES:

Patients with hypertension and diabetes are at greater risk of cardiovascular and renal disease and consequently have a more stringent recommended target BP goal of <130/80 mm Hg. Most patients require treatment with a combination of at least two antihypertensive agents in order to achieve their recommended goal BP, especially high-risk subgroups, and use of complementary antihypertensive drug classes is advocated in such patients.(15)(16)

Of the 1,940 patients who entered the eight week pivotal study, 261 had a medical history of diabetes. The data demonstrated the ability of AZOR to reduce blood pressure in the diabetes patient cohort. The diabetic patients treated with AZOR 10/40 mg were able to reduce their mean BP 30/18 mm Hg from an average baseline BP of 169/101 in the total cohort. This result was similar in comparison to patients without diabetes treated with AZOR 10/40 mg who were able to reduce their mean BP 30/19 mm Hg from an average baseline BP of 163/102 in the total cohort.

Important safety information

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, AZOR should be discontinued as soon as possible. See WARNINGS AND PRECAUTIONS, Fetal/Neonatal Morbidity and Mortality.

Hypotension in Volume- or Salt-Depleted Patients

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients, symptomatic hypotension due particularly to the olmesa
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
3. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
4. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
5. Minimally Invasive Treatment Reduces Shoulder Pain From Tendonitis
6. Smokefree Workplace Law Reduces Heart Attacks 59% Among Nonsmokers, New Research Shows
7. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
8. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
9. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
10. Study Finds Starion Instruments Tissue Welding Technology Reduces Pain and Bleeding in Tonsillectomy Patients
11. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" research ... http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging of ... orthopedic instrument industry has seen rapid development ... 3.28 billion yuan in 2006 to 9.85 billion yuan ...
(Date:1/15/2014)... 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has ... - Global Industry Analysis, Size, Share, Growth, Trends And ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... on patients in order to treat dental impairments, for ...
(Date:1/15/2014)... WASHINGTON , Jan. 15, 2014 AARP Foundation today ... support older adults suffering from the severe cold weather that ... are committed to helping those in need; so to support ... dollar-for-dollar contributions up to $250,000, which could mean up to ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... ST. LOUIS, Oct. 25, 2011 HIGHLIGHTS:2011 ... Q3 2011 reported sales increased 11% to ... products and Fine Chemicals ("SAFC") sales growing organically by 4% ... and changes in foreign currency exchange rates contributed an additional ...
... Company (NYSE: LLY ) has updated its full-year 2011 ... company,s Xigris ® product. Lilly expects to incur ... and contractual commitments related to Xigris. The exact amount of the ... in the range of $75.0 million to $95.0 million (pre-tax), or ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13Lilly Provides Update on 2011 Financial Guidance Due to Xigris Withdrawal 2
(Date:7/9/2014)... may smell of flatulence and have a reputation for being ... hydrogen sulfide is now being being found to offer potential ... stroke, heart attacks and dementia. A new compound (AP39), designed ... key to future therapies, by targeting delivery of very small ... inside cells. , Scientists in Exeter have already found ...
(Date:7/9/2014)... conducted by researchers at Tufts University School of Dental ... and developmental disabilities, the likelihood of having cavities decreased ... The findings, published in the July/August issue of ... designed to address the oral health of individuals in ... records of 107 patients at one of the eight ...
(Date:7/9/2014)... , , , , , ... , , , , , ... binaural recording using KEMAR, the weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... ... , , , , ... , , , , , ...
(Date:7/9/2014)... Keck School of Medicine of the University of ... a specific component of the immune system are ... of infection. The discovery suggests that blocking this ... human autoimmune and hyper-inflammatory diseases such as rheumatoid ... was published online on June 23 in ...
(Date:7/8/2014)... LIVERMORE, Calif. The Department of Defense,s Defense ... National Laboratory (LLNL) up to $2.5 million to ... to record and stimulate neurons within the brain ... week. , The research builds on the understanding ... in certain regions of the brain encode information, ...
Breaking Medicine News(10 mins):Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... unawares, leading to heart failure and even death. This ... valve// or arterial diseases and congenital heart defects, but ... in the bloodstream. ,In a paper to ... Nature Structural and Molecular Biology, a Rutgers-Newark researcher and ...
... first group of Electronic Health Record (EHR) products ... Records// Vendors Association (EHRVA) recognizes this achievement and ... accelerate EHR adoption. ,“EHRVA works to ... the significant value they provide to patients, providers, ...
... Researchers from Florida Atlantic University, the Center for Breast ... Hospital, and MeVis, The Center for Diagnostic// Systems and ... new techniques to aid clinicians in the diagnosis and ... developed and piloted a unique software platform utilizing computational ...
... in Australia to the grant of patent application to ... discovery of RNAi has been withdrawn.// This was announced ... of Massachusetts Medical School. The opposition was originally filed ... Announcement of the withdrawal will be published in Australia's ...
... insufficient oxygen supply to the heart as the critical ... a hypothermic state.// ,Writing in the July ... Physiology, researchers found no significant difference in the amount ... to one hour of severe hypothermia and rats exposed ...
... Pradesh government to stop functioning of all but one medical ... ,The court asked the state government not to ... ,The order was passed by Justice Sunil Ambawani on a ... ban on quacks in the state., ,However, the court ...
Cached Medicine News:Health News:Heart disease and strokes connected to a motor protein mechanism 2Health News:EHRVA Supports EHR Product Certification 2Health News:New Tool to Diagnose and Treat Breast Cancer 2Health News:New Tool to Diagnose and Treat Breast Cancer 3Health News:Heart Has Enough Oxygen to Survive Hypothermia; CPR Crucial 2Health News:Heart Has Enough Oxygen to Survive Hypothermia; CPR Crucial 3
Suture Cutter, 15 Up Curve...
Portal accessory instrument set. Set also includes a package of 8 mm Guide Wires (.15 cm x 38 cm), and Sterilization Tray....
...
Knot tier...
Medicine Products: